News

Published on 11 Oct 2021 on Zacks via Yahoo Finance

Company News for Oct 11, 2021


Article preview image

Share of Accolade, Inc. ACCD gained 4.3% after the company reported second quarter fiscal 2021 loss of $0.43 per share, lower than the Zacks Consensus Estimate of a loss of $0.45. ChemoCentryx, Inc.’s CCXI shares surged 96% after the company announced that the Food and Drug Administration has given approval to its Anca-associated vasculitis therapy.Shares of Allogene Therapeutics, Inc. ALLO plummeted 46.1% after the Food and Drug Administration put a hold on its cancer drug trials after chromosomal abnormality was detected in a single patient.Shares of Walmart, Inc. WMT advanced 0.3% after the retailer announced it holiday season plans that include the launch of a direct-to-home wine delivery service.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Walmart Inc. (WMT) : Free Stock Analysis Report ChemoCentryx, Inc. (CCXI) : Free Stock Analysis Report Allogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report Accolade, Inc. (ACCD) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research

NASDAQ.ACCD price evolution
NASDAQ.ALLO price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Is ChemoCentryx (CCXI) Stock Outpacing Its Medical Peers This Year?

For those looking to find strong Medical stocks, it is prudent to search for companies in the gro...

Zacks via Yahoo Finance 6 Oct 2022

Why Is ChemoCentryx (CCXI) Up 1.4% Since Last Earnings Report?

A month has gone by since the last earnings report for ChemoCentryx (CCXI). Shares have added abo...

Zacks via Yahoo Finance 7 Sep 2022

How Covid, 'industrial logic' and a threat played out in a multibillion-dollar biotech merger

Amgen Inc.'s persistence and patience won out in a 29-month saga that landed it a Peninsula compa...

American City Business Journals 1 Sep 2022

Aerie (AERI) Rallies 205.6% in the Past Three Months: Here's Why

Shares of Aerie Pharmaceuticals AERI have skyrocketed in the past three months, outpacing other m...

Zacks via Yahoo Finance 31 Aug 2022

Top Analyst Reports for Alphabet, Goldman Sachs & Anheuser-Busch

Wednesday, August 31, 2022 The Zacks Research Daily presents the best research output of our anal...

Zacks via Yahoo Finance 31 Aug 2022

Amgen (AMGN) Outperforms Industry Year to Date: What's Next?

Amgen AMGN has a diverse and growing portfolio of medicines in large therapeutic categories that ...

Zacks via Yahoo Finance 30 Aug 2022

What Biotech ETFs Might Be Right for Your Portfolio?

ETFS Biotech is back. For those who want to invest through exchange-traded funds, here are some c...

The Wall Street Journal 19 Aug 2022

ChemoCentryx (CCXI) Now Trades Above Golden Cross: Time to Buy?

After reaching an important support level, ChemoCentryx, Inc. (CCXI) could be a good stock pick f...

Zacks via Yahoo Finance 16 Aug 2022

Here's Why ChemoCentryx (CCXI) is a Great Momentum Stock to Buy

Momentum investing is all about the idea of following a stock's recent trend, which can be in eit...

Zacks via Yahoo Finance 16 Aug 2022

The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex...

For Immediate Release Chicago, IL – August 12, 2022 – Zacks.com announces the list of stocks feat...

Zacks via Yahoo Finance 12 Aug 2022